摘要
目的 探讨无抽搐电休克治疗难治性强迫症的疗效及安全性。方法 ３９例经氯丙咪嗪（＞１５０ｍｇ／ｄ）治疗８周效果差的强迫症患者，分为两组。一组加用无抽搐电休克治疗，每周３次共１０次，期间氯丙咪嗪减量；另一组继续服用原有氯丙咪嗪治疗。进行临床疗效、Ｙ－ＢＯＣＳ、ＴＥＳＳ评定并作比较。结果 合用无抽搐电休克治疗组显效率７１．４３％，与单用氯丙咪嗪组（５．５６％）相比有非常显著性差异。疗程结束时两组Ｙ－ＢＯＣＳ评分有非常显著性差异。ＴＥＳＳ评分无差异。结论 并用无抽搐电休克治疗难治性强迫症有效、安全。
Objective The purpose of the study was to determine the clinical efficacy and safety of adding MECF to clomipramine-refractory obsessive-compulsive disorder. Methods 39 patients who had failed to respond to an adequate trial of clomipramine( > 150 mg/d)for at least 8 weeks. 21 of the 39 pations (group 1) were treated with the combination of MECT and reduced clomipramine (100 mg/d); and the others (group 2) remained on clomipramine alone. Response and side effects to MECF augmentation and clomipramine alone were determined by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Treatment Emergent Symptoms Scale (TESS). Results All of the 21 patients were able to tolerate combined treatment, 15 (71.43%) had substantial reductions in obsessive-compulsive symptoms within 4 weeks of MECT course (three times per week). There was significant difference in efficacy between group 1 and group 2, but not in side effects. Conclusions These results sug- gest that MECT augmentation is effective and well tolerated in pations with clomipramine-refractory obsessive-compulsive disorder.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2001年第5期324-325,共2页
Chinese Journal of Nervous and Mental Diseases
关键词
无抽搐电休克
氯丙咪嗪
强迫症
治疗
对照研究
Modified electriconvulsive therapy Clomipramine Obsessive-compulsive disorder
